Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

BACKGROUND: To determine whether changes in the metabolism of metastatic renal cell carcinoma (mRCC) assessed by F18-FDG-PET after 14 and 28 days of treatment with tyrosine kinase inhibitors can predict overall and progression- free patient survival. METHODS: Thirty-nine consecutive patients with mR...

Descripción completa

Detalles Bibliográficos
Autores principales: Farnebo, Jacob, Grybäck, Per, Harmenberg, Ulrika, Laurell, Anna, Wersäll, Peter, Blomqvist, Lennart K, Ullén, Anders, Sandström, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064288/
https://www.ncbi.nlm.nih.gov/pubmed/24906441
http://dx.doi.org/10.1186/1471-2407-14-408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064288/
https://www.ncbi.nlm.nih.gov/pubmed/24906441
http://dx.doi.org/10.1186/1471-2407-14-408

Ejemplares similares